Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects

The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects

Independent Data Monitoring Board to review interim data from approximately 200 initial subjects